Muromonab-CD3
Showing 1 - 25 of >10,000
Leukemia, Acute Lymphocytic (ALL), Leukemia, Myeloid, Acute(AML), Leukemia, Myeloid, Chronic(CML) Trial in Memphis (device,
Completed
- Leukemia, Acute Lymphocytic (ALL)
- +7 more
- CliniMACS
- +11 more
-
Memphis, TennesseeSt. Jude Children's Research Hospital
Apr 3, 2020
![](/image/sponsor/kazakhstan's_medical_university_"ksph")
Health Status of Children Born After Assisted Reproductive
Recruiting
- Children Born After Assisted Reproductive Technologies
- +2 more
- hemogram examination
-
Almaty, KazakhstanSevara ilmuratova
Oct 17, 2023
Pediatric Cancer, Hodgkin Disease, CD30-Positive DLBCL Trial in Milwaukee (anti-CD30 Bispecific Antibody-armed
Not yet recruiting
- Pediatric Cancer
- +11 more
- anti-CD30 Bispecific Antibody-armed anti-CD3-Activated Autologous T-cells (CD30 biAb-AATC)
-
Milwaukee, WisconsinChildren's Wisconsin
Sep 14, 2022
Solid Tumor Trial (BS006 Injection)
Not yet recruiting
- Solid Tumor
- BS006 Injection
- (no location specified)
Jul 3, 2023
AML, Childhood Trial in United States (CD33*CD3 BsAb)
Active, not recruiting
- AML, Childhood
- CD33*CD3 BsAb
-
Birmingham, Alabama
- +12 more
Jan 12, 2023
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia, BCR-ABL1 Fusion Protein
Recruiting
- Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- +7 more
- Blinatumomab
- +3 more
-
Houston, TexasM D Anderson Cancer Center
Dec 31, 2022
Acute Myeloid Leukemia Refractory, Acute Myeloid Leukemia, in Relapse Trial in Xuzhou (anti Tim-3/CD123 CAR-T cell therapy)
Recruiting
- Acute Myeloid Leukemia Refractory
- Acute Myeloid Leukemia, in Relapse
- anti Tim-3/CD123 CAR-T cell therapy
-
Xuzhou, Jiangsu, ChinaKailin Xu
Nov 4, 2023
Recurrent B Acute Lymphoblastic Leukemia, Recurrent Mixed Phenotype Acute Leukemia, Refractory B Acute Lymphoblastic Leukemia
Recruiting
- Recurrent B Acute Lymphoblastic Leukemia
- +3 more
- Blinatumomab
- +2 more
-
New Haven, Connecticut
- +6 more
Jul 9, 2022
Colorectal Cancer Trial (Administration of CC-3)
Not yet recruiting
- Colorectal Cancer
- Administration of CC-3
- (no location specified)
Aug 11, 2023
Malignant Glioma, Glioblastoma Trial in Durham (hEGFRvIII-CD3 (BRiTE), Activated Cell Therapy)
Not yet recruiting
- Malignant Glioma
- Glioblastoma
- hEGFRvIII-CD3 (BRiTE)
- Activated Cell Therapy
-
Durham, North CarolinaDuke University Medical Center
Jun 24, 2022
Immune Markers in Pediatric ITP
Not yet recruiting
- ITP - Immune Thrombocytopenia
- complete blood count, CD3+ , CD4+ , CD8+, CD16+, CD56+, IFN-γ.
- (no location specified)
Oct 17, 2023
Relapsed Non Hodgkin Lymphoma, Relapsed Adult ALL, Relapsed Pediatric ALL Trial in Calgary, Edmonton (autologous CD19-directed
Recruiting
- Relapsed Non Hodgkin Lymphoma
- +2 more
- autologous CD19-directed chimeric antigen receptor (CAR) T-cells
-
Calgary, Alberta, Canada
- +5 more
Jul 18, 2022
Advanced Prostate Cancer Trial in Lyon, Villejuif, Rotterdam (JNJ-78278343, JNJ-87189401)
Not yet recruiting
- Advanced Prostate Cancer
-
Lyon, France
- +2 more
Oct 18, 2023
Glioblastoma Multiforme of Brain Trial in Duarte (CHM-1101 CAR-T cells)
Not yet recruiting
- Glioblastoma Multiforme of Brain
- CHM-1101 CAR-T cells
-
Duarte, CaliforniaCity of Hope Medical Center
Dec 19, 2022
Leukemia, Inborn Errors of Metabolism, Bone Marrow Failure Syndromes Trial in Philadelphia (Transplant of stem cells with
Recruiting
- Leukemia
- +4 more
- Transplant of stem cells with CD3+/CD19+ depletion (CliniMACs)
-
Philadelphia, PennsylvaniaChildren's Hospital of Philadelphia
Nov 2, 2021
Non Hodgkin's Lymphoma Trial in Beijing (TRAC and Power3 Genes Knock-out Allogeneic CD19-targeting CAR-T cell (ATHENA CAR-T),
Not yet recruiting
- Non Hodgkin's Lymphoma
- TRAC and Power3 Genes Knock-out Allogeneic CD19-targeting CAR-T cell (ATHENA CAR-T)
- +2 more
-
Beijing, China
- +2 more
Aug 23, 2023
Acute Myeloid Leukemia, T Cell Acute Lymphoblastic Leukemia, T Cell Lymphoblastic Lymphoma Trial in Milwaukee (XmAb18968 - Dose
Recruiting
- Acute Myeloid Leukemia
- +2 more
- XmAb18968 - Dose level -1
- +4 more
-
Milwaukee, WisconsinFroedtert Hospital & the Medical College of Wisconsin
Feb 15, 2022
Classical Hodgkin Lymphoma, Non-Hodgkin Lymphoma Trial (GEN3017)
Not yet recruiting
- Classical Hodgkin Lymphoma
- Non-Hodgkin Lymphoma
- GEN3017
- (no location specified)
Aug 25, 2023
CNS Lymphoma Trial in Duarte (procedure, biological, drug)
Recruiting
- Central Nervous System Lymphoma
- Aspiration
- +10 more
-
Duarte, CaliforniaCity of Hope Medical Center
Dec 8, 2022
Primary Immunodeficiency, PID Trial in Pittsburgh (CD3/CD19 neg allogeneic BMT)
Active, not recruiting
- Primary Immunodeficiency
- PID
- CD3/CD19 neg allogeneic BMT
-
Pittsburgh, PennsylvaniaChildren's Hospital of Pittsburgh of University of Pittsburgh Me
Oct 6, 2021
Non Small Cell Lung Cancer, Solid Tumor Trial in Jette, Brussel (Avelumab, Ipilimumab 5 MG/ML, Pembrolizumab 100 MG in 4 ML
Recruiting
- Non Small Cell Lung Cancer
- Solid Tumor
- Avelumab
- +3 more
-
Jette, Brussels, Belgium
- +1 more
Sep 9, 2022
CD20-positive Non-Hodgkin Lymphoma Trial in China (EX103 injection)
Recruiting
- CD20-positive Non-Hodgkin Lymphoma
- EX103 injection
-
Zhengzhou, Henan, China
- +3 more
Aug 28, 2023
Non-hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma Trial in Boston (CD79b-19 CAR T cells,
Not yet recruiting
- Non-hodgkin Lymphoma
- +9 more
- CD79b-19 CAR T cells
- +2 more
-
Boston, MassachusettsMassachusetts General Hospital
Sep 6, 2023
Sickle Cell Disease Trial in Paris (DREPAGLOBE drug product)
Active, not recruiting
- Sickle Cell Disease
- DREPAGLOBE drug product
-
Paris, FranceDepartment of Biotherapy, Necker-Enfants Malades Hospital
Sep 26, 2022